Navigation Links
Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
Date:12/7/2007

a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which is in a Phase 1 clinical trial in advanced cancer patients; RDEA806 for gout, which is expected to enter a Phase 2 efficacy trial in the first half of 2008. Ardea also is developing a next-generation NNRTI and a next-generation MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of having active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases in the first half of 2008, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... For the first time, chemists have succeeded in measuring ... time resolution. The study reveals how vibration of a ... groups. , The study was performed at the ... from the University of Jyvskyl works as a visiting ... in the study. The second team was lead by ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... Minimally Invasive Treatment of Bone Fractures Achieves Significant ... Feb. 23 IlluminOss Medical Inc., a medical ... Stabilization System for orthopedic surgery, today announced that ... Registration issued by BSI (British Standards Institute). ...
... February 23 Health Robotics and Can-Med,today ... agreement whereby Can-Med,has acquired the exclusive distribution ... Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, Turkmenistan, Kyrgyzstan, ... only automated, point-of-care-distributed, and fail-safe,robotic system for ...
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
Cached Biology Technology:IlluminOss Medical Receives ISO 13485 Certification 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3
(Date:8/20/2014)... E. Fox, a John and Rebecca Moores Professor of Biology ... a fellow in the International Society for the Study of ... of four members two from the U.S., one from ... 2014. Fellows are elected every three years, and 36 have ... more than 20 countries, the ISSOL includes researchers from disciplines ...
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... of the Para and Mato Grosso states of Brazil. ... in order to deforest the land. Deforestation is the ... the land is thereafter converted to a nonforest use. ... ranches, or urban use. The herringbone-patterned tan lines cutting ... the middle of the image are evidence of deforestation ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... children with autism have a wide range of genetic ... genetic test to identify the disorder. Now, University of ... in the facial features and brain structures of children ... to develop a formula for earlier detection of the ...
... Woods Institute for the Environment has awarded five faculty ... that help solve the world,s urgent demands for fresh ... and well-being, yet in poor countries more than a ... and more than 2 billion lack basic sanitation facilities," ...
... and marrow transplant physician Naynesh Kamani, MD ... new national clinical trial of unrelated donor marrow and ... cell disease . Children,s National will join more than ... clinical trial of this treatment. If successful, the Sickle ...
Cached Biology News:Researchers study facial structures, brain abnormalities to reveal formula for detection of autism 2New planning grants to fund research on freshwater issues 2New planning grants to fund research on freshwater issues 3Children's national co-leads nationwide study of landmark sickle cell treatment 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... cell culture scale-up, these culture chambers produce ... 10 9 range and are useful ... flasks. • High mechanical • strength and ... to shipping • Certified nonpyrogenic and sterilized ...
Biology Products: